Kiran Devisetty, MD, FASTRO

449 posts

Kiran Devisetty, MD, FASTRO banner
Kiran Devisetty, MD, FASTRO

Kiran Devisetty, MD, FASTRO

@KiranDevisetty

Senior Director, Clinical Development, Interventional Oncology at Johnson & Johnson; tweets=my own

Philadelphia, PA Katılım Nisan 2013
463 Takip Edilen894 Takipçiler
Kiran Devisetty, MD, FASTRO retweetledi
Rehema J. Thomas, MD
Rehema J. Thomas, MD@RadiantRehemaMD·
Thank you to our 🔥 panelists! Dr. Sushil Beriwal, @tomboike, @KiranDevisetty, & @tjroycemd. Amazing insight into careers in industry and the overlap with clinical roles. We are still clinicians at the end of the day! 🥼 Had so much fun moderating!! @ARRO_org @ASTRO_org #ARRODay
ARRO@ARRO_org

Come see our first panel for career opportunities and leadership outside of the clinic, happening now! Thank you to our panelists pictured below!

English
2
3
11
3.1K
Kiran Devisetty, MD, FASTRO retweetledi
David Sher
David Sher@DavidSherMD·
Absolutely terrific thread here on ENI dosing for oropharyngeal cancer, touching not just on recent data but on how new standards are established. Just a few thoughts on top of well-articulated arguments for different approaches. (1/n)
Matt Spraker@SprakerMDPhD

Educate me please, #RadOnc. A poll! Given the exciting #ASCO24 H&N dose de-escalation results (30 Gy), will you be decreasing elective dose going forward?

English
4
19
52
35.5K
Kiran Devisetty, MD, FASTRO retweetledi
Salma Jabbour
Salma Jabbour@SalmaJabbour1·
ADRIATIC study is the new standard of care for limited stage small cell lung cancer followed by adjuvant durvalumab with improved mOS to 56 mo from 33 mo (placebo) and mPFS of 17 months with durvalumab vs 9 mo (placebo) #ASCO24
Salma Jabbour tweet mediaSalma Jabbour tweet mediaSalma Jabbour tweet mediaSalma Jabbour tweet media
English
0
10
40
3K
Kiran Devisetty, MD, FASTRO retweetledi
Krishan Jethwa
Krishan Jethwa@KrishanJethwa·
🚨🚨RTOG 0848🚨🚨 Anatomically resectable PDAC randomized postoperatively 1st randomization: Gemcitabine +/- erlotinib (no benefit with erlotinib) 🔥2nd Randomization🔥 +/- Chemoradiation, 50.4 Gy/28 fx + cape ✅⬆️ DFS w/ ☢️ ✅N0, ⬆️DFS and OS (5y 48% vs 29%) w/ ☢️ #asco24
Krishan Jethwa tweet mediaKrishan Jethwa tweet media
English
12
56
131
56.6K
Kiran Devisetty, MD, FASTRO retweetledi
Jeff Ryckman
Jeff Ryckman@jryckman3·
@IBCradiation One thing is for sure, I’d be less likely to omit RT for low ER+! 10y local failure of 18.8% on PRIME2 😳 (read: most favorable candidates for omission. >= 65y, < 3 cm (only 10% 2-3 cm), pN0, SM >= 1mm, G1-2 (only 3% G3), LVSI (4%), G3 AND LVSI excluded)
Jeff Ryckman tweet media
English
0
8
23
2.2K
Kiran Devisetty, MD, FASTRO retweetledi
Joe Y Chang
Joe Y Chang@JoeChangMD·
Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal, published in Europe Journal of Cancer today. Here is the personalized Share Link:
authors.elsevier.com/a/1ihIj_Lqip9w…
Joe Y Chang tweet mediaJoe Y Chang tweet mediaJoe Y Chang tweet media
English
0
11
50
3.7K